Trial Profile
A Phase III study of SPK-8011 for hemophilia A
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Jul 2020
Price :
$35
*
At a glance
- Drugs Dirloctocogene samoparvovec (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Sponsors Spark Therapeutics
- 12 Jul 2020 According to a Spark Therapeutics media release, dosing participants in this Phase 3 stduy is expected to occur in 2021.
- 19 Feb 2019 Status changed from planning to recruiting, according to the Spark Therapeutics media release.
- 02 Dec 2018 According to a Spark Therapeutics media release, the company intends to initiate this phase 3 run-in study by the end of 2018 to collect prospective observational data on trial participants.